Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone extension study in boys with DMD
NCT02760277Phase 2Completed
- Sponsor
- ReveraGen BioPharma
- Start
- Jul 2016
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by ReveraGen BioPharma. Started Jul 2016; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02760277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760277.